SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending after a strong earnings report and news of a massive AI lease deal, positioning the company as a key player in AI infrastructure. The community is excited about the potential for a short squeeze and analysts raising price targets, while also debating entry points and long-term prospects. Bullish sentiment is fueled by the company's growth in the AI data center space, with some comparing it to other high-flying stocks in the sector.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ ($LAES) is surging due to a strategic partnership focused on developing quantum-resistant chips for U.S. defense applications, fueling speculation about lucrative government contracts. The community is buzzing about the company's growth potential and comparing it to other players in the quantum computing space, with some investors believing LAES is undervalued and predicting a significant climb.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is gaining traction as community members express excitement, referencing an imminent listing on Moonshot and calling for others to "RAGE" harder. Fueling the hype, some are alluding to potential breakouts and increased liquidity, while others point to the project's roots in OG internet meme culture. The community's focus remains on strong community building and promoting the idea of everyone making it.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as chatter increases around a potential short squeeze, with the community noting high short interest and open call option volume. Recent developments, including a major financial endorsement and increased stake from Alphabet Inc., have boosted optimism. Discussions also involve TeraWulf's shift towards AI and high-performance computing, similar to peers in the sector.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as the community discusses its potential for significant growth, drawing comparisons to IREN's valuation and anticipating news related to AI/HPC ventures. Bullish sentiment is fueled by the company's strong Bitcoin holdings, infrastructure ownership, and a recent mining update, with many expecting a run to higher price targets. Additionally, some are speculating on government involvement and the potential for a short squeeze.

GSR III Acquisition Corp engages in the merger, share exchange, asset acquisition, share purchase or reorganization with one or more businesses. The company was founded on May 10, 2023 and is headquartered in Austin, Texas.

GSR III Acquisition Corp. - Ordinary Shares- Class A

GSR III Acquisition Corp. Ordinary Shares

GSRT is trending due to the imminent ticker change to NKLR following its merger with Terra Innovatum, a micro-modular nuclear reactor developer; the change is expected to occur soon. Community members are excited about the potential, drawing comparisons to OKLO and highlighting the growing demand for nuclear energy. Discussions also include the stock's valuation relative to its peers and expectations for increased volume and volatility post-ticker change.

One and one Green Technologies. Inc - Ordinary Shares - Class A

YDDL is trending due to its recent IPO and subsequent volatile price action, with the stock experiencing significant gains and drops. The community is actively discussing its low float, high insider ownership, and potential for both further gains and significant losses, with some expressing concerns about it being a pump and dump. Some traders are also looking at other AI and Green Tech names like $APLD and $HIVE.

Zoracles

Zoracles ($ZORA) is trending due to a recent listing on Robinhood, driving increased volume and attention from new investors. The community is excited about the potential exposure to Robinhood's user base and the possibility of further listings on major exchanges. Some community members are drawing comparisons to social media platforms and anticipating a broader altcoin season.

Creative Media & Community Trust Corp. is a real estate investment trust that seeks to own, operate, and develop premier multifamily and creative office assets in vibrant and emerging communities throughout the United States. It operates through the following segments: Office, Hotel, and Lending. The Office segment consists of the rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment involves the operation of hotel properties. The Lending segment focuses on loans to small businesses. The company was founded in 1993 and is headquartered in Dallas, TX.

Creative Media & Community Trust

CMCT is trending as traders discuss its potential for a short squeeze and parabolic moves, given its low float. Community members are debating its volatile history, reverse splits, and the possibility of a pump and dump, while also noting its current uptrend. Some traders are speculating about a potential break above key price levels that could trigger further gains.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is trending due to its strategic partnership with DoorDash, expanding its autonomous delivery reach and volume. Community members are discussing the potential for significant long-term growth, with some anticipating a rise to all-time highs. The stock is also gaining attention within the robotics sector, with some suggesting potential buyouts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cidara Therapeutics, Inc. (CDTX) on Thursday said that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its drug CD388 for the prevention of influenza A and B in adults and adolescents who are at higher risk of disease-related complications.The new designation is in addition to the Fast Track designation granted to the drug by the agency in June 2023. CEO Jeffrey Stein said that the designations underscore the importance of the drug as a potential new non-vaccine prophylactic for seasonal influenza.“Individuals who have chronic medical conditions, advanced age, or are immune compromised may not be adequately protected by current vaccines, leaving them at higher risk for infection and complications from flu. As a long-acting prophylactic drug, CD388’s activity does not rely on an immune response, making it a potential prevention option for high-risk individuals as well as those for whom vaccines are contraindicated,” he <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/09/3164062/0/en/Cidara-Therapeutics-Receives-U-S-FDA-Breakthrough-Therapy-Designation-for-CD388-in-Seasonal-Influenza-Prevention.html">added</a>.The Breakthrough Therapy designation was awarded to the drug based on the results of a study in which CD388 provided statistically significant prevention of seasonal influenza in healthy unvaccinated adults aged 18-64. The company is now looking toward advancing the drug through its ongoing late-stage trial.The Breakthrough Therapy designation is intended to expedite the review of medicines that treat a serious or life-threatening condition. Benefits of the designation include eligibility for priority review and the FDA’s organizational commitment to involving senior management to guide the company on the most efficient route to approval, the company noted.Shares of the company rose 8% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CDTX">CDTX stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1360/118;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_09_at_12_16_14_PM_png_11f3dc4644.webp" alt="CDTX's Sentiment Meter and Message Volume as of 12:16 p.m. ET on Oct. 09, 2025 | Source: Stocktwits" width="1360" height="118"><figcaption>CDTX's Sentiment Meter and Message Volume as of 12:16 p.m. ET on Oct. 09, 2025 | Source: Stocktwits</figcaption></figure>H.C. Wainwright analyst Sara Nik subsequently raised the firm’s price target on Cidara Therapeutics to $150 from $110 while keeping a ‘Buy’ rating on the shares. The new price target implies a potential upside of over 52% from the stock’s closing price on Wednesday.CDTX stock nearly quadrupled in value this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lyft-partners-with-tensor-to-deploy-hundreds-of-avs-on-its-platform/ch67uQtR3KC">Lyft Partners With Tensor To Deploy Hundreds Of AVs On Its Platform</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cidara Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral

The Breakthrough Therapy designation was awarded to the drug based on the results of a study in which CD388 provided statistically significant prevention of seasonal influenza in healthy unvaccinated adults aged 18-64.

Equity

The Breakthrough Therapy designation was awarded to the drug based on the results of a study in which CD388 provided statistically significant prevention of seasonal influenza in healthy unvaccinated adults aged 18-64.


Defender Capital, a long-term shareholder of STAAR Surgical Company, on Tuesday expressed opposition to the firm’s proposed acquisition by Alcon Inc.Defender Capital owns 1.5% of STAAR’s common stock. “The proposed sale of STAAR to Alcon for $28 per share significantly undervalues the company, especially when considering the STAAR board of directors' rejection of Alcon's previous offer for $58 per share in cash only sixteen months ago,” the shareholder said.Defender Capital further <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/defender-capital-opposes-staar-surgicals-proposed-sale-to-alcon-302577240.html">added</a> that it sees no compelling reason to sell STAAR at this time, with recent optimistic projections and outlook. The shareholder also expressed disappointment at the company board, alleging that the proposed transaction is ‘ill-advised’ and does not reflect STAAR’s prospects as a standalone company.Shares of <a href="https://stocktwits.com/symbol/STAA">STAAR Surgical</a> Company traded nearly 2% lower on Tuesday. On Stocktwits, retail sentiment around STAA stock stayed within the ‘bearish’ territory while message volume remained at ‘normal’ levels.Defender Capital is not the only one to oppose the proposed acquisition. Last month, Hong Kong-headquartered investment management firm Yunqi Capital, which holds a 5.1% stake in STAAR, <a href="https://stocktwits.com/news-articles/markets/equity/staar-surgical-shareholder-yunqi-capital-opposes-proposed-merger-with-alcon/chDQFDHR32a">alleged</a> in a letter to other shareholders that it would not necessarily be opposed to a potential merger of the two companies at an appropriate price or on other appropriate terms, but opposed the deal on the terms announced in August.Before Yunqi, Broadwood Partners, L.P., and its affiliates also announced their intention to vote against the proposed acquisition. Broadwood is STAAR’s largest shareholder, owning 27.5% of the company’s outstanding common shares.STAAR is a manufacturer of phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Alcon said in early August that the companies have entered into a definitive merger agreement under which Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash. The transaction is expected to close in about six to 12 months and represents a total equity value of approximately $1.5 billion, it added.STAA stock is up 8% this year and down approximately 23% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ford-shares-slump-after-reports-of-fire-at-aluminum-supplier-plant/ch6PW0NR3ha">Ford Shares Slump 5% After Reports Of Fire At Aluminum Supplier Plant: Retail Dismisses The Dip As ‘Short-Lived’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Editor's Note: The story has been updated to reflect Broadwood Partners' accurate stake in STAAR Surgical Company.

Global stock market chart and trading board - stock photo

STAAR Surgical’s Long-Term Shareholder Says Proposed Deal With Alcon Undervalues The Company

Defender Capital, which owns 1.5% of STAAR’s common stock, highlighted STAAR’s board of directors' rejection of Alcon's previous offer of $58 per share in cash.

Lexeo Therapeutics (LXEO) announced on Tuesday that the company is considering a smaller pivotal study for LX2006 in the treatment of Friedreich's ataxia (FA) cardiomyopathy, scheduled to begin in the first half of 2026, pending finalization of the study protocol.The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.lexeotx.com/news-releases/news-release-details/lexeo-therapeutics-announces-progress-fda-discussions">data</a> from the planned pivotal study will be pooled with data from the ongoing Phase I/II studies of LX2006 to support an approval application to the U.S. Food and Drug Administration for the therapy, the company stated after discussions with the agency.Lexeo will submit enhanced manufacturing comparability data and meet an additional nonclinical requirement before the initiation of the planned pivotal study to enable pooling, the company added.Lexeo is continuing to engage with the agency regarding the protocol of the pivotal study, it stated, adding that it believes this regulatory feedback has the potential to reduce the size and duration of the planned pivotal study. The company is also optimistic that the feedback may accelerate the overall timeline to an application submission.Updated interim clinical data from both ongoing Phase I/II studies of LX2006 show sustained or deepening improvements in the majority of participants across both cardiac and neurologic measures of Friedreich’s ataxia, the company said.FA cardiomyopathy is the leading cause of death in individuals with Friedreich’s ataxia (FA), a rare, inherited neurodegenerative disorder causing progressive damage to the nervous system, leading to impaired balance, muscle coordination, and sensory loss, often beginning in childhood. It is estimated to affect approximately 5,000 people in the U.S.Shares of the company rallied 24% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LXEO">LXEO stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1368/120;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_9_19_18_AM_png_3d23b7c692.webp" alt="LXEO's Sentiment Meter and Message Volume as of 9:19 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1368" height="120"><figcaption>LXEO's Sentiment Meter and Message Volume as of 9:19 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>LXEO stock has risen 22% this year and but fallen by approximately 6% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-reportedly-slashes-workforce-at-its-us-wegovy-manufacturing-plant/ch6PBqJR3WD">Novo Nordisk Reportedly Slashes Workforce At Its US Wegovy Manufacturing Plant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process

The company stated that data from a planned pivotal study will be pooled with data from the ongoing Phase I/II studies of LX2006 to support an approval application to the U.S. Food and Drug Administration for the therapy. 

H.C. Wainwright raised its price target on AnaptysBio (ANAB) to $59 from $38 on Tuesday, following the company's announcement of its plan to split its business into two.The analyst kept a ‘Buy’ rating on the shares. The new price target implies a potential upside of about 154% to the stock’s closing price on Monday.AnaptysBio <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-intent-separate-biopharma-operations">stated </a>on Tuesday that its board of directors approved plans to explore separating its business into two independent, publicly traded companies. Upon completion of the split, the royalty management company will manage royalties and milestone payments from financial collaborations, including Jemperli with GSK and Imsidolimab with Vanda, with a focus on protecting and returning their value, the company said.The royalty management company is expected to require minimal infrastructure and staff, and will operate under a new name, it added.Meanwhile, the other company, referred to as Biopharma Co., will focus on biopharmaceutical operations, including the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases, such as Rosnilimab, ANB033, and ANB101. After the split, Biopharma Co. will launch with adequate capital to fund operations for at least two years and will also operate under a new name, the company stated.The separation is expected to be completed by the end of 2026. Anaptys CEO Daniel Faga is expected to continue as CEO of the biopharma company.Shares of the company traded 30% higher on Tuesday afternoon at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ANAB">ANAB stock</a> rose from ‘bullish’ to ‘extremely bullish territory’ over the past 24 hours, while message volume increased from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_12_21_38_PM_png_239792a64d.webp" alt="ANAB's Sentiment Meter and Message Volume as of 12:21 p.m. ET on Sept. 30, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>ANAB's Sentiment Meter and Message Volume as of 12:21 p.m. ET on Sept. 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they now expect the stock to crater.<stembedurl>https://stocktwits.com/CommercialREbroker/message/630482537</stembedurl>ANAB stock has more than doubled this year but dropped nearly 10% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-amends-deal-with-sanofi-broadens-partnership/chDDB6dR3BH">Novavax Amends Deal With Sanofi, Broadens Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an AnaptysBio logo is displayed on a smartphone screen in Athens, Greece on January 13, 2023. (Photo illustration by Nikolas Kokovlis/NurPhoto via Getty Images)

AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level

H.C. Wainwright’s new price target of $59 implies a potential upside of about 154% to the stock’s closing price on Monday. 

MBX Biosciences, Inc. (MBX) said on Monday that its once-weekly Canvuparatide achieved the primary endpoint with statistical significance at week 12 in its mid-stage trial in adult patients with chronic hypoparathyroidism.Hypoparathyroidism is a rare endocrine disease caused by a deficiency of parathyroid hormone (PTH) released by the parathyroid glands that results in decreased calcium levels in the blood. According to MBX, the disease affects more than 250,000 individuals in the U.S. and Europe.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.mbxbio.com/news-releases/news-release-details/mbx-biosciences-announces-once-weekly-canvuparatide-achieved">noted</a> that 63% of Canvuparatide-treated patients in the study maintained serum calcium levels within the normal range and were independent of conventional therapy, including active vitamin D and calcium supplements, at week 12, with zero contribution from rescue therapy, compared to 31% in placebo-treated patients, the company stated.In the open-label extension of the trial, 79% of patients who received treatment achieved these milestones at six months. The company is now preparing to kickstart a late-stage trial of once-weekly Canvuparatide in 2026.Shares of the company soared 144% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MBX">MBX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.Guggenheim subsequently raised its price target on MBX to $84 from $44 while keeping a ‘Buy’ rating on the shares. The results achieved the firm's "bull case," noted the analyst, who increased the firm's view of the odds of success for Canvuparatide to 75% from 50% previously. Guggenheim also argued that the data provides "clear line of sight to blockbuster-plus potential."CEO Kent Hawryluk said that the company is pleased with the results. “We believe the totality of the data support a once-weekly product profile with continuous infusion-like PTH exposure. These 12-week and 6-month results represent the potential for a meaningful improvement over current treatment options for HP patients and provide a strong foundation for further development,” he said.All doses of Canvuparatide were generally well-tolerated with no discontinuations related to the drug, and no treatment-related serious adverse events or discontinuations were recorded during the 12-week trial, the company said.MBX stock is down 46% this year and approximately 55% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/staar-surgical-shareholder-yunqi-capital-opposes-proposed-merger-with-alcon/chDQFDHR32a">STAAR Surgical’s Shareholder Yunqi Capital Opposes Proposed Merger With Alcon – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

MBX Stock Soars Pre-Market After Investigational Hypoparathyroidism Drug Yields Positive Results In Study

The company is now preparing to kickstart a late-stage trial of once-weekly Canvuparatide in 2026.

Krispy Kreme (DNUT) shares jumped over 6% before the bell on Thursday and witnessed a 633% increase in retail user message count on Stocktwits in the last 24 hours after FBI Director Kash Patel reportedly noted the company has a “good investment” opportunity.According to Bloomberg News, during his testimony in Congress, Patel was asked about his purchase of individual stocks while in office. The report added that Patel explained he has “long liked” to trade stocks.Patel noted that he saw “good investment” opportunities in Krispy Kreme and ON Semiconductor Corp. (ON), according to the report. “I just follow certain industries,” he said at the hearing, “and I thought they would be a good investment.”A user on Stocktwits noted that it was “crazy” that a Senate oversight meeting led to a boost in stock price for a donut company.<a href="https://stocktwits.com/Werewolfoflondon/message/629073308">https://stocktwits.com/Werewolfoflondon/message/629073308</a>Retail sentiment on <a href="https://stocktwits.com/symbol/DNUT">Krispy Kreme</a> jumped to ‘bullish’ from ‘bearish’ territory a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.<figure class="image"><img style="aspect-ratio:795/97;" src="https://news.stocktwits-cdn.com/DNUT_sentiment_png_f84903838d.webp" alt="DNUT sentiment.png" width="795" height="97"><figcaption>DNUT sentiment and message volume September 18, 2025, as of 7 am ET | Source: Stocktwits</figcaption></figure>In July, Patel&nbsp;had&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://static.notus.org/3b/61/46d6712d4aff9412d01276fbf797/kashyap-patel-07-21-2025-278t.pdf">disclosed</a> that he had purchased between $15,000 and $50,000 worth of Krispy Kreme shares and between $50,000 and $100,000 worth of ON Semiconductor shares.Bloomberg noted that Joe Neguse of Colorado directed the question to Patel in the context of a growing bipartisan initiative aimed at prohibiting members of Congress from trading individual stocks.The report said that the proposed measure is part of a broader campaign to strengthen anti-corruption safeguards and that, notably, officials in the executive branch, such as Patel, would remain exempt from the restrictions under the current proposal.Shares of Krispy Kreme have declined 68% this year and lost 74% of its value in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nike-shares-are-rising-premarket-heres-why/chDcAX9R3Gt">Nike Shares Are Rising Premarket: Here's Why</a>

The Krispy Kreme corporate logo is displayed on a sign at their store on January 31, 2025 in San Diego, California. (Photo by Kevin Carter/Getty Images)

Krispy Kreme Stock Pops After FBI Director Kash Patel Reportedly Endorses It As A ‘Good Investment’: Retail Chatter Soars Over 600%

According to a Bloomberg News report, Patel noted during his testimony in Congress that he saw “good investment” opportunities in Krispy Kreme and ON Semiconductor Corp.

Wolfpack Research announced on Thursday its short position in EV maker Faraday Future (FFAI) and opined that it would likely revert to being a penny stock before eventually delisting.The firm <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wolfpackresearch.com/items/ffai%3A-this-house-of-cards-is-falling-apart-as-yt-jia%E2%80%99s-latest-pump-is-built-on-fake-orders-and-a-tsunami-of-lies">stated</a> that it believes the latest pump in stock value was based on “fake orders, a rebadged Chinese minivan and a tsunami of lies” intended to induce retail investors to buy ahead of dilution.FFAI’s stock jumped on July 22 after Nature’s Miracle announced a preorder of 1000 EV minivans in a deal worth up to $100 million. However, Wolfpack thinks this is fake, provided that Nature’s Miracle does not have the cash to make such a purchase. Further, the founder of Nature’s Miracle and Faraday Future CEO Jia Yueting were classmates in business school, the firm noted.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/FFAI">FFAI stock</a> remained within ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.Wolfpack alleged, citing former employees and media reports, that the EV minivan called the FX Super One is a rebadged vehicle from Chinese automaker Great Wall Motors. The over 10,000 pre-orders for the vehicle are all non-binding, including the one made by Nature’s Miracle, it added.While the company recently announced $82 million of new financing, Faraday didn't reveal the financier, and Wolfpack believes this may be a reiteration of prior financing rounds where the CEO and other insiders appear to have used fronts to disguise that they were the ultimate source of funding. The firm also raised doubts about how the CEO has money to fund the company after emerging from his personal bankruptcy. “We think he hid assets from the bankruptcy court,” it said, while adding that this includes homes on the California coast and shares of Lucid.The ultimate goal of these moves by the company appears to be to pump up the stock ahead of massive dilution, Wolfpack alleged. FFAI is slated to vote on September 19 to increase the authorized common share count by 39% and issue shares to certain convertible note and warrant holders.YT Jia returned as co-CEO of the EV maker in April earlier this year after stepping down in 2019. However, Wolfpack believes this was “theater” since he was running the company even while he was not in the CEO position.FFAI stock is down 29% this year and approximately 57% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ford-supplier-magna-international-appoints-former-timken-executive-as-cfo/chwNkSJRdvj">Ford Supplier Magna International Appoints Former Timken Executive As CFO</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Faraday Future logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Wolfpack Research Reveals Short Position In EV Maker Faraday Future

The firm stated that it believes the latest pump in stock value was based on “fake orders, a rebadged Chinese minivan and a tsunami of lies” intended to induce retail investors to buy. 

Rapport Therapeutics, Inc. (RAPP) on Monday said that a mid-stage clinical trial of RAP-219 in patients with drug-resistant focal onset seizures demonstrated a statistically significant reduction in long episodes over the 8-week treatment period.RAP-219 also <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.rapportrx.com/news-releases/news-release-details/rapport-announces-positive-topline-results-phase-2a-clinical">demonstrated</a> a statistically significant and clinically meaningful reduction in seizures accompanied by physical signs compared with baseline in the study, the company said, while adding that it plans to advance the investigational therapy into two late-stage trials in the third quarter of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RAPP">RAPP stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels. Shares of the company traded 204% higher in the pre-market session at the time of writing.<figure class="image"><img style="aspect-ratio:575/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_08_at_8_06_25_AM_png_a5918d7983.webp" alt="RAPP's Sentiment Meter and Message Volume as of 8:15 a.m. ET on Sept. 8, 2025 | Source: Stocktwits" width="575" height="61"><figcaption>RAPP's Sentiment Meter and Message Volume as of 8:15 a.m. ET on Sept. 8, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded optimistic, saying the update is ‘great news.’<stembedurl>https://stocktwits.com/Mushichka/message/627808704</stembedurl>Another user, however, expressed doubts about whether the data warrants the massive rally.<stembedurl>https://stocktwits.com/Trader_Tom/message/627805877</stembedurl>H.C. Wainwright subsequently raised its price target on Rapport to $34 from $31 while keeping a ‘Buy’ rating on the shares. The firm states that RAP-219 surpassed its "most bullish expectations" and added that the data provides "unimpeachable evidence" of the drug's effect, offering "strong evidence that it has the potential to become a mainstay" in the treatment of focal onset seizures. The firm increased its probability of success for oral RAP-219 to 66% and its peak revenue estimate to $766 million, up from $613 million.Focal onset seizures are seizures that begin in one area of one brain hemisphere, causing symptoms that typically affect one side of the body or are limited to a specific sensation, emotion, or movement. In the trial, Rapport enrolled 30 patients, 18 men and 12 women, with focal onset seizures who had an implanted RNS System, a brain simulation device for drug-resistant focal epilepsy. The patients received 0.75 mg of RAP-219 oral tablets daily for 5 days, followed by 1.25 mg of RAP-219 oral tablets daily for the remainder of the 8-week treatment period.During the treatment period, over 85% patients achieved more than or equal to 30% reduction in long episodes from baseline, the company said, while 72% achieved more than or equal to 50% reduction. Twenty-four patients also achieved seizure freedom, the company said. Reduction in long episodes (LEs) is an objective electrographic biomarker for clinical seizure reduction, it said.RAP-219 was generally well-tolerated in the trial, with the majority of treatment-emergent adverse events being mild and a low discontinuation rate, the company added.Rapport plans to hold an end-of-mid-stage trial meeting with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025. The company also expects to present additional efficacy analyses and 8-week follow-up results in 2026 and to initiate a trial to evaluate the long-term safety of the therapy in patients by the end of 2025. RAP-219 is also being evaluated in bipolar mania and diabetic peripheral neuropathic pain.RAPP stock is down 19% this year and approximately 27% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pnc-to-buy-colorado-first-bank-for-4-1-b-in-push-to-bolster-national-reach/chwWxbxRdrR">PNC To Buy Colorado’s FirstBank for $4.1B In Push To Bolster National Reach: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened

The company said that it now plans to advance the investigational therapy into two late-stage trials in the third quarter of 2026. 

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) jumped 4% in the pre-market session on Monday after its drug Tonmya received the U.S. Food and Drug Administration’s (FDA) approval for the treatment of fibromyalgia in adults.Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts an estimated 10 million adults in the U.S., mostly women, and symptoms include chronic widespread pain and fatigue, among others.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1585/tonix-pharmaceuticals-announces-fda-approval-of">announced</a> the approval on Friday evening. Tonmya is a non-opioid, once-daily bedtime analgesic designed for rapid absorption into the bloodstream. It is also the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years, Tonix said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TNXP">Tonix</a> trended in the ‘extremely bullish’ territory over the past 24 hours, coupled with ‘extremely high’ message volume. According to Stocktwits data, retail chatter around the stock jumped 72% over the past 24 hours and by 281% over the past seven days.<figure class="image"><img style="aspect-ratio:566/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_18_at_8_26_39_AM_png_c112eeec38.webp" alt="TNXP's Sentiment Meter and Message Volume as of 8:25 a.m. ET on Aug. 18, 2025 | Source: Stocktwits" width="566" height="62"><figcaption>TNXP's Sentiment Meter and Message Volume as of 8:25 a.m. ET on Aug. 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user dismissed hopes for a massive rally, adding that ‘this is a marathon not a sprint.’<stembedurl>https://stocktwits.com/AlwaysABullNeverABear/message/625581652</stembedurl>Another user said they see significant market potential for the drug.<stembedurl>https://stocktwits.com/GeneralAdam/message/625580421</stembedurl>In two late-stage trials, Tonmya significantly reduced fibromyalgia pain compared to placebo at 14 weeks. The drug was generally well-tolerated in late-stage trials, and a greater percentage of study participants taking Tonmya experienced a clinically meaningful improvement in their pain after three months, compared to placebo. Tonmya is expected to be available for adult patients in the U.S. with fibromyalgia beginning in the fourth quarter of this year.TNXP stock is up by 56% this year and by over 15% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-slips-under-116000-while-cardano-solana-lead-altcoin-selloff/chsO7iYRdQw">Bitcoin Slips Under $116,000 While Cardano, Solana Lead Altcoin Selloff</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years, Tonix said. 

ProShares Trust - ProShares Ultra Russell 2000 2X Shares

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$47.49
Prev Close	$48.09
Open	$48.00
Dividend Yield	N/A
50-Day Moving Average	$43.72
Beta	N/A
Avg. Volume	523,036.19
PE Ratio	N/A

52-Week High	$51.87
52-Week Low	$24.47
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

UWM
ProShares Ultra Russell2000

Feed

News

Sentiment

Fundamentals

Info

Latest UWM News

UWMProShares Ultra Russell2000